Predictive Oncology INC. 8-K Filing
Ticker: AGPU · Form: 8-K · Filed: Nov 17, 2025 · CIK: 1446159
Sentiment: neutral
Filing Stats: 533 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-11-17 08:00:51
Key Financial Figures
- $0.01 — ch registered Common stock, par value $0.01 per share POAI NASDAQ Capital Marke
Filing Documents
- f8k_111625.htm (8-K) — 23KB
- exh_991.htm (EX-99.1) — 25KB
- exh991_01.jpg (GRAPHIC) — 329KB
- exh991_02.jpg (GRAPHIC) — 138KB
- exh991_03.jpg (GRAPHIC) — 118KB
- exh991_04.jpg (GRAPHIC) — 97KB
- exh991_05.jpg (GRAPHIC) — 178KB
- exh991_06.jpg (GRAPHIC) — 95KB
- exh991_07.jpg (GRAPHIC) — 99KB
- exh991_08.jpg (GRAPHIC) — 199KB
- exh991_09.jpg (GRAPHIC) — 183KB
- exh991_10.jpg (GRAPHIC) — 119KB
- exh991_11.jpg (GRAPHIC) — 192KB
- exh991_12.jpg (GRAPHIC) — 123KB
- exh991_13.jpg (GRAPHIC) — 209KB
- exh991_14.jpg (GRAPHIC) — 170KB
- exh991_15.jpg (GRAPHIC) — 215KB
- exh991_16.jpg (GRAPHIC) — 217KB
- exh991_17.jpg (GRAPHIC) — 142KB
- exh991_18.jpg (GRAPHIC) — 97KB
- 0001171843-25-007372.txt ( ) — 4239KB
- poai-20251117.xsd (EX-101.SCH) — 3KB
- poai-20251117_lab.xml (EX-101.LAB) — 33KB
- poai-20251117_pre.xml (EX-101.PRE) — 22KB
- f8k_111625_htm.xml (XML) — 4KB
01 Regulation
Item 7.01 Regulation FD Disclosure. Predictive Oncology Inc. (the "Company") has scheduled a conference call and webcast at 9:00 a.m. Eastern Time on November 17, 2025, to discuss the Company's financial results for the third quarter ended September 30, 2025 and provide an update on its digital asset strategy. A presentation will be made available on the Company's investor relations page. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information included in this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Presentation dated November 17, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Predictive Oncology Inc. Date: November 17, 2025 By: /s/ Josh Blacher Josh Blacher Chief Financial Officer